Revised supplemental figures from Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor–Sensitive and -Resistant Chronic Myeloid Leukemia

Figure S1. Inhibition of Axl by shRNA. Figure S2. Assessment of half maximal inhibitory concentration (IC50) for BGB324 in human CD34+ cells from healthy donors. Figure S3. Treatment with BGB324 increased apoptosis and decreased proliferation of CML cell lines. Figure S4. Reduction of BCR-ABL and Crkl phosphorylation by imatinib. Figure S5. Treatment with imatinib and BGB324 does not induce an additive inhibitory effect on phosphorylation of Erk and Akt. Figure S6. BCR-ABL and Crkl phosphorylation are not affected by imatinib or BGB324 in KCL-22 T315I mutated cells. Figure S7. Colony forming assay using primary CD34+ cells isolated from healthy donors treated for 72 h with 1, 3 or 5 μM of BGB324 (n=2). Figure S8. BGB324 increases apoptosis of primary CML cells.